Categories

Above the Fold

TECH: Cerner stock keeps going up

Cerner’s stock price is up another 5% today. It’s P/E is nearing 45.  And this is for a company that basically sells more services (i.e. consulting) than software. No doubt that the re-architecting of their technology back in the last Millenium paid off big time, but this recent spurt really is on no new news, other than GE overpaid for IDX.

But does this mean that one of the oft-mentioned candidates for takeover (Oracle is a frequent mention, but any big tech firm might do) is having another look?  Or would the really ballsy play to be shorting Cerner here? Here’s the chart, and yes we should all have bought in May.

Cern

Technorati: , , , , , ,

POLICY: Jamie Robinson on Managed Consumerism–innovative but missing the bigger picture.

Jamie Robinson is one of the best and brightest of the “younger” crop of health economists in America, and certainly has his ear to the ground of what’s going on in American health care in a way that few others (aside from Uwe Reinhardt who anyway I’d classify as being in the “elder” generation of health economists) seem to understand. He was one of the first in academia to see the potential of the capitated physician groups, and was also one of the first to understand the end of managed care. Most academics spend forever mining the archaeology of the longly dead. Jamie sticks closely to the recent past and hints at the future.

His latest, one of numerous articles in a bursting at the seams Health Affairs, is on Managed Consumerism. It’s an attempt, and not a bad one, to put a unified framework around both the CDHP movement and managed competition:

“consumerism and managed competition often are proposing different solutions to different problems, not different and incompatible solutions to the same problems.”

Robinson spends a little time explaining that the two come from different philosophies. Consumerism from individual consumers making choices at time of care mostly from solo docs paid fee for service and therefore, (not that he says it) politically promoted by those doctors. Managed competition relies on consumers making choices among different integrated HMOs/health plans which use multi-specialty groups that are incented to keep costs down (or at least neutral) by use of capitation and pre-payment. He goes onto note not why managed competition failed, but instead that health plans stopped using the techniques of managed care (such as small networks and utilization management). What he doesn’t say but what is true is that the regulation (the management part of “managed competition”) was never in place to force plans to do so, despite the fact that Alain Enthoven had worked out the mechanism a decade earlier. (BTW for those of you who care, the mechanism involves pooling large numbers of people, forcing health plans to offer them the same set of benefits, and making the people choose between health plans with actual post-tax dollars, thereby giving the health plans the incentive to reduce overall costs per population). That never happened in any population, because it requires substantial reform of the insurance market (We’ll get to that later, even if Robinson doesn’t). Because that never happened, managed care never put the mechanisms in place that consistently would reduce costs, and instead when push came to shove (and the system pushed back) managed care meekly gave up.  And then the managed care plans noticed that they could make more money just being old fashioned insurance companies.

Five years into that inflation spiral, employers and consumers are moaning again, and so now we get the plan that looks like a 1970s major medical with a high deductible, but we can dress it up and call it a consumer-directed plan…and it’s much better. Of course it remains a high deductible plan that is basically unmanaged beyond the deductible, and it by definition doesn’t do much to control the costs of the expensive people on whom (as all you THCB readers should know by now) 80% of the money is spent on.

So what is going to happen. I’m skipping his optimistic bit but here’s the pessimism

“Ever-higher consumer cost sharing and ever-tighter provider networks would threaten the efficiency and equity of the health care delivery system. Excessive consumer cost sharing reduces the social pooling of risk, transferring financial responsibility from the healthy to the sick, and potentially reduces efficiency by reimbursing episodic and acute care services more generously than preventive and chronic care services. Excessively narrow provider networks frustrate patients’ ability to match their preferences with provider characteristics and limit providers’ ability to compete broadly on the basis of price and quality at the time of care”

What Jamie thinks is coming next is of course the managed high deductible plan

“It is not hard to envisage high-deductible, narrow-network, tightly managed product designs where choice of providers and procedures is limited by consumers themselves in favor of affordability.

What comes next in his analysis is at once very useful and interesting, and also misses the point. He provides a schematic about how insurance companies should buy medical care from providers. He argues that they should change their benefits based on whether or not the service being received is either demand or supply inelastic….i.e. whether changing the way its paid for can influence the patient the provider or both.

Rob

 

As witnessed in this chart (Exhibit 2–click on it to see it more clearly), this is pretty innovative stuff, and I’m sure that lots of big consulting shops are even now stealing it to take to their insurance clients.

Robinson does something similar for the clinical care market by dividing it up into acute and chronic care episodes and whether or not there are efficiencies of scale in delivery systems or not. And there are some good additions that his confluting together the consumer world (the 80% of the people) with the managed care world (the 80% of the dollars) provides. Rightfully, he accuses the proponents of managed competition and CDHC of extrapolating essentially from the institutions they know, and his framework at least covers the real world.

But he starts to lose me when he concludes that the market has spoken and rejected the managed competition approach.

This is the moment for a second generation of consumer-driven health policies and products. The shortcomings of HMOs, capitation, IDSs, and the other components of managed competition have opened the way for alternative approaches to using market mechanisms for improving the health care system

Writing in the same issue of Health Affairs in an excellent piece that points out many of the foibles of consumer directed health care Bob Berneson of the Urban Institute points out what was right about Enthoven’s original vision

In the right hands, market competition ideas can be made consistent with this ethos. Alain Enthoven’s managed competition approach, for example, in the words of Uwe Reinhardt, was an attempt to “fuse a price-competitive framework for health care with production processes designed to produce medical treatments efficiently and with income transfers designed to achieve a desired level of social equity.” This sounds fine to me, because it might have been done in ways that did not threaten the foundation of trust. It’s just that markets haven’t followed Enthoven’s vision—for lots of reasons.

So Enthoven’s vision required regulatory reform that was not allowed to happen, because in the end it would have been bad for the providers of health care’s fiscal interests. Robinson knows that the real world won’t let theories like his work.  He even notes (even before it’s fully happened, not that it’ll be a secret to THCB readers) what’s going to go wrong with consumer-directed care.

However, consumer-driven health care suffers from its own shortcomings. Blunt cost-sharing provisions, unadjusted for the patient’s income or health status, will penalize the poor and the sick while allowing their wealthier and healthier compatriots to retain higher balances in their HSAs. Nonselective network designs, the dismantling of utilization management, and a reversion to fee-for-service payment will encourage spending for high-cost services that fall above the insurance deductible.

But while he believes that there is a chance for managed consumerism, he’s ignoring two factors that will cause managed consumerism to be the failure that both managed care has been and consumer directed health care is about to be.

First, the market for clinical care is dominated by policies and regulations set in the 1930s and 1960s, and that’s why we have the institutions (solo practice docs, FFS medicine, and more latterly physician-owned surgicenters and now specialty hospitals) that fit neatly into Robinson’s new chart but don’t make any real sense for the way health care ought to be delivered in any rational market, or for that matter in a state-designed system. So in the absence of massive reform, there is still no real way that we are going to have a system that does any better than provide the players in the system with what they think will be best for them. Hence the strongest proponents of HSAs have forever been the solo practice docs who in their delusion believe that it will enable them to directly bill their patients and get the insurance companies out of the middle. The political power of the providers (sometimes aligning the docs with and sometimes opposing them to the hospitals) will continue to push against any rationalization of their organization or behavior. So the management part of managed consumerism is seeking a fix from the workings of an invisible hand that providers will just bite off.

Second, and this is the crucial bit, the market for insurance — irrespective of how insurers pay doctors and providers — is rigged so that insurers are better off insuring healthy people. Robinson calls his section on how insurers pay providers The Market For Insurance Coverage. But he’s wrong, the market for insurance coverage is about how people buy health insurance, not how health insurers buy or contracts for care. In the US most people are going to continue to have insurance covered by their employer or the taxpayer irrespective of how much it costs. This drives to the heart of the problem. Because we live in a rich country with a virtually inelastic demand for care, and because upper income employees receive health care for which they are not aware of the cost at the insurance level or the provider level, the system can always increase its prices — knowing that it will increase its revenue more from the price increase than it will lose it by the price effect.

Of course some people can’t afford it (or their employers can’t) and they get tossed into the uninsured numbers. But because no-one is responsible for them, and no-one (i.e. no central government) has to concern itself with the overall costs, no one cares. The provider keeps doing more, and the insurer has the choice of doing the hard things and beating them down (which is expensive and inefficient) or the easy thing which is selecting its risks better and jacking up its rates to its clients.  It’ll lose a few, but no matter as it’ll stay more profitable on the ones it keeps.  Robinson know this very well, as it’s a story he told about Aetna in Health Affairs last year.

And as Paul Krugman wrote yesterday in the NY Times in his “Healthcare Economics 101” column, the real issue is that the market for health insurance cannot be solved in an efficient or frankly humane way if we don’t have a universal pool. In other words it needs to be “rigged” so that insurers are no longer better off insuring healthy people. That at least was the concept behind managed competition, and it’s the same concept behind single payer, et al. It was not the concept behind market-driven managed care and is the complete anathema to consumer directed health care as exists now (and will in the future given that United has bought Golden Rule). And that is the elephant in the room that Robinson fails to note, for all the innovation in his schema.

Without real insurance reform, whatever we do we are never going to solve the core problems of cost (or even cost-effectiveness) and uninsurance. Anything else is lipstick on the pig.

Technorati: , , <a href="http://technorati.com/tag/insurance, , , ,

PHARMA/POLICY: GAO confirms the corruption of science forced on the FDA

Just in case there was any doubt that the White House’s filthy fingerprints were all over the Plan B non-decision, the Congressional GAO is out with a  report that call the FDA’s Plan B decision process ‘unusual’. And of course points out that senior FDA leadership (i.e. Crawford and his cronies) forced this over the heads of the FDA staffers responsible for such decisions, and even made the decision before the evidence was in.

The GAO probe found that high-level FDA officials were more involved than is usually the case in decisions to approve drugs for over-the-counter use. Also, investigators found conflicting accounts as to whether the decision to reject the application for OTC use was made before the agency’s reviews were finished, the report said. Also, three FDA directors who normally would have been responsible for approving the decision to reject the application did not do so because they disagreed with it, the report found.

This is only one small battle in the war to keep the creationists and fundamentalists loons outside of science. A battle that we’ve lost.

Technorati: , , , , , , ,

BLOGS: Typepad apologises for hassles

So I managed to lose some work because of Typepad’s system problems last week. They have apologized and offered all their users a free month/fortnight/45 days rebate.  Very nice of them.

I also lost some work (hence no long post today) because late last night I hit Ctrl-W by mistake when I meant to hit Shift-W.  That’s a windows command/shortcut that closes the window you’re in, and when it’s an I-Explorer window like the one using Typepad (or any other program which is hosted), it closes and you’ve lost whatever you haven’t saved. And of course it happens when you haven’t saved for 20 minutes….really maddening. And of course as it’s Microsoft you cannot turn that feature off.

So I’m now trying out client side blog editors. I’ve suggested to Type pad that they should create their own, or cut a deal with the best one.  they referred me to w.bloggar, but having used it, it doesn’t have a live WISYWIG editor. Sad, cos it looks powerful and it’s free. Blogjet is only free for 30 days but as it has got such an editor I’m trying it out now.  I’ll be back with the long post on topic tomorrow instead.

POLICY/POLITICS: Health Reform may be back on the national agenda

Here’s my editorial from FierceHealthcare this morning.

This week may or may not have been a political harbinger for the coming years. Following a disastrous year for the Administration, Democrats have been claiming victory following wins in Virginia, New Jersey and California. Meanwhile, voters in California and Washington rejected measures that would have limited the activities (and incomes) of drug companies and trial lawyers. In Massachusetts, there may be the start of a compromise designed to get universal insurance (of a sort) for the state, and several other states are looking at the issue. Of course, nationally this will only mean something if the Democrats really carry their (so far modest) victories into the Congress next year and the White House in three years. That of course is a long time away. But health care is fast becoming the number one domestic issue and a Democratic majority will feel compelled to have another crack at it.

POLICY: Did you need more evidence that being poor and sick is bad for your financial health?

No, you’ve seen plenty including what’s being described in various places as my "smackdown" of Medpundit last week. but in case you weren’t quite satisfied, another liberal bleeding heart group (reported by capitalist tools Forbes of all people) has found in a survey of low income people (mostly those in households earning under $35,000) that medical debt is prevalent. Nearly half (46%) have got it, and as little as $500 in medical debt can restrict access to housing, can contribute towards forclosure, bankruptcy et al. Note that more than 40% of those with medical debt had health insurance at the time they ran up the debt. Which means that those Americans who haven’t stashed away their $2,000 for deductibles et al in their HSAs are going to be the road-kill of those driving the HSA/CDHP bus.  But you knew that anyway, right?

The survey is from The Access Point, and the press release is here. The methodology looks sound to me and it back up plenty of prior research about the subject that tells us what we already know.

PBMs: The future of PBMs–a work in progress

There’s an interesting article in AISHealth.com’s Business News of the Week called Why the Plans of a Major Drug Purchasing Coalition Did Not Work. The quick story is that a group of employers got together in late 2004 and made an attempt to negotiate pricing direct with the pharma companies.  The pharma companies, who are quite happy with the way they work with the PBMs, and who also realized that this coalition was too small (only 53 companies and 5 million lives) to matter, and that they could easily face them down. And that’s what happened.

But instead the companies involved were rounded up by their benefit consultant (Hewitt) and demanded a more transparent approach from their PBMs. So they have got that with some smaller PBMs (Medimpact, Aetna & Walgreens) offering to supply "transparent" services.  That is, tell them what rebates they are getting and therefore the true price they are paying for drugs. Now this is very very early days. No one has actually switched over to using these plans yet and won’t until next year. Plus more importantly given the buying power of the big 3 (Medco, Caremark and Express Scripts) it’s very likely that the transparent PBM will still have a price disadvantage overall. And that is before the big 3 target the transparent guys in a price war for their clients.

However, we may be seeing a bigger sea change as a Federal Appeals court yesterday upheld a Maine state law that said that PBMs must reveal to their Maine customers what rebates they get, and must have the best interests of their clients at heart when they negotiate with drug companies. (Stop and think about what that last sentence says about the PBMs’ behavior thus far!!)

Now this information does not have to be made public (and I’m sure PBMs will design contracts banning their clients from revealing that information). The PBMs of course will fight this to the Supreme Court and fight it state by state. And of course if you believe their public statements, all this fuss about them making money off rebates and price gouging their clients (not to mention bribing health plans) can’t possibly be true. No sir, No way. Here’s what Express Scripts’ CEO Barrett Toan said about these accusations in Health Affairs earlier this year.

Atlas: Let’s turn to some challenges to the PBM business model. Critics of PBMs assert that PBMs’ way of doing business is inherently at odds with the interests of their customers. Recent actions by various state governments and others seem to bear out this concern. Practices that at minimum raise eyebrows are (1) accepting rebates and administrative fees from drug manufacturers whose products PBMs give preferential status in their formularies, and then retaining unspecified portions of these sums rather than passing them along to customers; (2) paying health plans, ostensibly for data on plan members’ prescription drug usage, in return for securing the health plans’ business; and (3) leveraging the purchaser relationship to steer business away from retail pharmacies to mail-service pharmacies that the PBMs themselves own and that in fact generate large percentages of PBMs’ profits. How do you respond to these critics?Toan: Those are theories. To understand the actual PBM practices, you need to know the details. Those kinds of concerns are overblown because the actual marketplace will not allow those practices to exist.First, the rebates. Express Scripts will not accept any other form of revenue from a manufacturer except in the form of rebates, which are actually discounts from their prices plus administrative fees that are associated with those rebates. We negotiate at arm’s length through a closed bid process run on a two-year cycle. Those bids are opened, and we essentially have our rebates defined. We make those rebate offers known to our customers; that helps them shape their formularies. We pass on a majority of the rebate dollars to the plan sponsor, which can audit the actual payments made by the manufacturers. There’s a great degree of transparency in the rebating process. The idea that these are secret deals, black boxes, is a canard coming from people who oppose what we’re doing—which is making drugs more affordable and a little bit safer.On the issue of whether PBMs should pay plan sponsors for data, we have a very strict policy on that, and I would assume other PBMs have similar policies. First, the amount of money that’s paid to help a group implement its program—for instance, if it has to issue new ID cards or send around new formularies—is reimbursed at fair value. Each of our clients certifies that these are legitimate costs, so that we can be sure that we’re reimbursing for services that had to be provided. Paying data fees is not a practice we would be comfortable with unless there were a very big direct benefit. We do some research that requires an integrated database, so having de-identified medical records can be useful in performing important research. But again, any consideration that might be given for something should be strictly justified based on the actual value to the PBM.

I’ll have more to say about this when the piece Jane Sarasohn-Kahn and I have written on The Prescribing Infrastructure comes out soon, but suffice it to say that "he would say that wouldn’t ‘e". (For those of you who don’t know the quote, go read your early ’60s British scandal history) But in some senses, this battle is part of the last war.  The bigger PBMs are slowly turning to making their money via their mail order services and doing more generic substitution. And of course they now have the Medicare program to mine. Although eventually, I think that will hurt their margins….but eventually is a long time!

PHARMA/PHYSICIANS/POLICY: Oncologists getting paid for reporting data they should report anyway, by Gregory D. Pawelski

Congress has authorized the payment for oncologists reporting whether their treatment adheres to guidelines. Greg Pawelski, who follows the oncology market very carefully, was not too impressed.
When Senate Finance Committee Chairman Chuck Grassley found out that the value of the approximately $300 million-a-year medicare chemotherapy demonstration project to report on a patient’s level of nausea, vomiting, pain and fatigue was for nothing (providers were being paid $130 to simply forward the data that is already collected), they hoodwinked Congress into additional reimbursement to oncologists that report whether their treatment adheres to practice guidelines published by either NCCN or ASCO.

Looks like cancer patients will have to continue overpaying their oncologists and not have access to cutting-edge cancer treatments, and continue to suffer side-effect consequences and even death. The system will continue to serve the clinical investigators and the clinical oncologists, but not serve the best interests of cancer patients.

I think that the concept that some "authoritative" organization (made up primarily of practitioners and researchers with built in conflicts of interest) should determine the "correct" approach to cancer treatment has been very harmful to progress.

BLOGS: Open thread

For those of you wanting to go on at more than 250 words about the health policy competition, how I’m an unfair censor or anything else that takes your fancy. Post your coments in this thread. (I can’t easily move comments so the only real option I had was to delete the previous ones)

For those of you who want to take up Eric’s challenge, which we’ll run for a couple of weeks please go to this post and put it in the comments. But remember 250 words or less and ON topic. Or I will delete them from there.

PHARMA/POLICY/POLITICS: Slick Willie syphons off big Pharma

Today is waste of money election day in California, brought to you mostly by the soon-to-be terminated Governor Arnold. But there are two other props on the ballot on which PhRMA has dropped more than $80 million to muddy the already muddied waters. It looks like Prop 78 which is nominally the one big Pharma "wants" to win and Prop 79 which is the one they actually want to lose (and the reason 78 is on the ballot) are both going down to defeat. Nonetheless I’ve had a voice message from someone claiming to be a surgeon in Fresno telling me to vote yes on 78, paid for by a host of drug companies (and admitting it as such, which is why I don’t think they want it to win).

But of course the really smart people in this state are extracting as much green from big Pharma as they can. The smoothest political operator of them all, former Speaker of the State House and former Mayor of San Francisco and the man whom is surrounded by but never touched by corruption Willie Brown, has successfully put some $500,000 of big pharma’s money in his pocket. Apparently he’s got the trial lawyers to stay neutral and conned some of the NAACP (who also know which way their bread it buttered) to actually support it. Way to go Willie! Sadly that gravy train will be over after today.

assetto corsa mods